EIB and UCB join forces to accelerate 'best-in-class' research pipeline | UCB
UCB's Global Corporate Website

EIB and UCB join forces to accelerate 'best-in-class' research pipeline

Posted by
Fabian Seunier, Corporate Merger & Acquisitions
26-Jun-2014
The European Investment Bank (EIB) and UCB are partnering  to help us turn some of the promising compounds in our research and development (R&D) pipeline into new medicines. This is the first partnership of its kind between a biopharmaceutical company and the EU's long-term funding institution and it is aimed to accelerate advances in medical science.

Through this partnership, EIB and UCB have co-designed a new way of funding medical research by which EIB will share the risks and potential rewards inherent to drug development. The Bank's “at risk co-development funding” will make up to €75 million available for the development of selected UCB compounds. UCB and EIB will engage in the co-development process through a Joint Steering Committee. In return, EIB will receive payments when and if predefined milestones are met. This is inventive in the worlds of finance and research.

EIB greatly appreciated UCB’s focus on bringing superior value to patients and described UCB's R&D pipeline and drug development expertise as 'best-in-class'. This has been a perfect match to EIB's ground-breaking approach to funding R&D.

This partnership now allows us to accelerate the development of our promising programmes and we are therefore thrilled that EIB chose UCB as the first company with which it will partner for this innovative funding scheme : successfully completing those developments will bring benefits to UCB, EIB and patients around the world.

Leave a Comment

By submitting your personal data, you agree with UCB's Data Privacy Policy. Furthermore, for more information on the terms of use of this website please visit our Legal Notice, accessible here.
7 + 1 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Comment:
Posted by HM, 26 September 2014

The Bank's “at risk co-development funding” will make up to €75 million available for the development of which selected UCB compounds, in particular?

Posted by UCB

While I’m not at liberty to disclose the specific names of the compounds, I can share that the EIB funding concerns 6 projects from our pipeline in both immunology and neurology, and at various stages of development. For more information don’t hesitate to contact me at laurent.schots@ucb.com